(P-377) Efficacy and Safety by Age After Switch to Doravirine/Islatravir (100 mg/0.25 mg) Once Daily: Week 48 Results from Two Phase 3 Randomized, Active-Controlled Studies in Adults Living with HIV-1

Monday, October 20, 2025

12:15 PM - 1:30 PM US ET

Location: Poster Hall B4-B5

Presenting Author(s)

FP

Frank A. Post, MD, PhD

King's College Hospital NHS Foundation Trust
London, England, United Kingdom
Moti Ramgopal, MD, FACP, FIDSA (he/him/his)

Medical Director
Midway Immunology and Research Center
Fort Pierce, FL, United States
MS

Marcel Stoeckle, MD

University Hospital Basel, University of Basel
Basel, Basel-Stadt, Switzerland
AC

Andrew Carr, MD

St Vincent’s Hospital
Sydney, New South Wales, Australia
Olayemi O. Osiyemi, MD

President
Triple O Research Institute PA, West Palm Beach, Florida, USA
West Palm Beach, Florida, United States
Ronald G. Nahass, MD

President
ID Care
Hillsborough, NJ, United States
HK

Harold P. Katner, MD

Chief of Infectious Disease Division
Mercer University School of Medicine
Macon, Georgia, United States
JS

Jason Szabo, MD, PhD

L'Actuel Medical Clinic
Montreal, Quebec, Canada
AG

Anjana Grandhi, PhD

Merck & Co., Inc.
Rahway, New Jersey, United States
MF

Monica Fuszard, MS

Merck & Co., Inc
Rahway, New Jersey, United States
SK

Stephanie O. Klopfer, PhD

Merck & Co., Inc.
Rahway, New Jersey, United States
RL

Rima Lahoulou, n/a

MSD
Puteaux, Haute-Normandie, France
LS

Luisa M. Stamm, MD, PhD

Merck & Co., Inc.
Rahway, New Jersey, United States
MF

Michelle C. Fox, MD

Merck & Co., Inc.
Rahway, New Jersey, United States
JK

Jason Y. Kim, MD, MSCE

Director, Clinical Research- Infectious Diseases
Merck & Co., Inc.
Kenilworth, NJ, United States